In a word, our research indicated that m6A-dependent nuclear ncRNA PANC754 interacts with its binding protein PSPC1 and chromatin-accessible histone H3K4me1 to form ncRNA/RBP/histone repression complex near promoter region can enhance immunotherapy capability of ICB anti-NKG2A against CRC through downregulation of the immune evasive LGALS7 signaling (Fig. 8C). Here, LGALS7 is linked to colorectal carcinoma.